Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,838 | 4 | 49.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,050 | 1 | 25.5% |
| Food and Beverage | $2,129 | 101 | 13.4% |
| Travel and Lodging | $1,112 | 4 | 7.0% |
| Honoraria | $550.00 | 1 | 3.5% |
| Education | $190.52 | 3 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $6,300 | 2 | $0 (2021) |
| Immunocore Limited | $3,918 | 9 | $0 (2023) |
| Lilly USA, LLC | $2,921 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $568.68 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $227.16 | 17 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $204.78 | 10 | $0 (2023) |
| Celgene Corporation | $153.10 | 6 | $0 (2024) |
| COMSORT, Inc | $150.00 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $142.89 | 6 | $0 (2024) |
| PFIZER INC. | $141.97 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $708.08 | 27 | Lilly USA, LLC ($108.33) |
| 2023 | $4,143 | 22 | Immunocore Limited ($3,918) |
| 2022 | $3,475 | 9 | Lilly USA, LLC ($2,813) |
| 2021 | $6,504 | 14 | Eli Lilly and Company ($6,300) |
| 2020 | $190.77 | 12 | GENZYME CORPORATION ($37.02) |
| 2019 | $368.11 | 14 | Incyte Corporation ($124.92) |
| 2018 | $406.54 | 12 | COMSORT, Inc ($150.00) |
| 2017 | $73.60 | 4 | Genentech USA, Inc. ($37.65) |
All Payment Transactions
114 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.63 | General |
| Category: Oncology | ||||||
| 11/14/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/25/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $18.40 | General |
| 10/17/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $49.99 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $13.95 | General |
| Category: Rare Disease | ||||||
| 09/19/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $13.18 | General |
| 09/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Oncology | ||||||
| 08/20/2024 | Lilly USA, LLC | VERZENIO (Drug) | Education | In-kind items and services | $108.33 | General |
| Category: Oncology | ||||||
| 08/14/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $13.52 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $78.74 | General |
| Category: Hematology | ||||||
| 05/16/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Oncology | ||||||
| 05/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $13.08 | General |
| 05/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Rare Disease | ||||||
| 03/27/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $16.33 | General |
| 02/22/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $27.34 | General |
| 02/09/2024 | Genentech, Inc. | Alecensa (Biological), Avastin, Columvi | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: BioOncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 360 | 723 | $260,544 | $69,094 |
| 2022 | 8 | 505 | 1,087 | $387,300 | $107,602 |
| 2021 | 12 | 640 | 1,202 | $401,545 | $118,588 |
| 2020 | 11 | 628 | 1,239 | $327,105 | $85,376 |
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 101 | 398 | $136,800 | $41,862 | 30.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 96 | 152 | $34,200 | $10,846 | 31.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 54 | 55 | $41,500 | $7,579 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $19,880 | $3,841 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 23 | $6,555 | $1,450 | 22.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 14 | 17 | $6,545 | $1,267 | 19.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $6,820 | $1,143 | 16.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 16 | 16 | $3,840 | $734.58 | 19.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 11 | 12 | $1,104 | $271.46 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $3,300 | $99.98 | 3.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 116 | 482 | $160,530 | $51,483 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 39 | 113 | $49,790 | $14,589 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 102 | 163 | $35,045 | $10,909 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 78 | 119 | $34,510 | $10,005 | 29.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 44 | $26,400 | $4,612 | 17.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 29 | $21,280 | $4,552 | 21.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 42 | $16,800 | $3,338 | 19.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $16,620 | $3,273 | 19.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 16 | 29 | $10,875 | $2,259 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 20 | 20 | $11,080 | $1,733 | 15.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 17 | 19 | $4,370 | $848.54 | 19.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 110 | 426 | $136,865 | $47,787 | 34.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 37 | 112 | $46,680 | $15,057 | 32.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 132 | 213 | $44,105 | $14,321 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 72 | 117 | $32,175 | $11,118 | 34.6% |
About Dr. Priyankkumar Patel, MD
Dr. Priyankkumar Patel, MD is a Internal Medicine healthcare provider based in Urbana, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2010. The National Provider Identifier (NPI) number assigned to this provider is 1437460789.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priyankkumar Patel, MD has received a total of $15,869 in payments from pharmaceutical and medical device companies, with $708.08 received in 2024. These payments were reported across 114 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($7,838).
As a Medicare-enrolled provider, Patel has provided services to 2,133 Medicare beneficiaries, totaling 4,251 services with total Medicare billing of $380,660. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Urbana, IL
- Active Since 07/01/2010
- Last Updated 03/23/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1437460789
Products in Payments
- KIMMTRAK (Drug) $3,918
- KEYTRUDA (Biological) $365.04
- JAKAFI (Drug) $124.92
- REBLOZYL (Biological) $110.92
- VERZENIO (Drug) $108.33
- XARELTO (Drug) $103.92
- PROMACTA (Drug) $90.61
- OPDIVO (Biological) $85.67
- PYRUKYND (Drug) $74.67
- Lenvima (Drug) $67.27
- IBRANCE (Drug) $64.80
- Padcev (Drug) $62.25
- IMBRUVICA (Drug) $57.25
- DARZALEX (Biological) $49.99
- CALQUENCE (Drug) $36.27
- LYNPARZA (Drug) $33.72
- Rubraca (Drug) $32.20
- IMFINZI (Drug) $32.03
- ULTOMIRIS (Biological) $29.28
- JEVTANA (Drug) $28.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Urbana
Dr. Michael Broman, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $38,603
Dr. Mbu Mongwa, M.d, M.D
Internal Medicine — Payments: $30,763
Dr. Ghurulakshmi Moorthy, M..d, M..D
Internal Medicine — Payments: $8,884
Job Mogire
Internal Medicine — Payments: $6,432
Mr. John Crankshaw, M.d, M.D
Internal Medicine — Payments: $5,935
Dr. Uday Kanakadandi, Md, MD
Internal Medicine — Payments: $5,908